Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

140 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I Trial of MCARH109, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma: An Updated Analysis.
Jurgens EM, Firestone RS, Chaudhari J, Hosszu K, Devlin SM, Shah UA, Landa J, McAvoy DP, Lesokhin AM, Korde N, Hassoun H, Tan CR, Hultcrantz M, Shah GL, Landau HJ, Chung DJ, Scordo M, Eren OC, Dogan A, Giralt SA, Park JH, Rivière I, Brentjens RJ, Smith EL, Wang X, Usmani SZ, Mailankody S. Jurgens EM, et al. Among authors: landau hj. J Clin Oncol. 2024 Dec 4:JCO2401785. doi: 10.1200/JCO-24-01785. Online ahead of print. J Clin Oncol. 2024. PMID: 39631041
Bortezomib, liposomal doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective treatment for patients with newly diagnosed multiple myeloma with Internatinal Staging System stage II or III, or extramedullary disease.
Landau H, Pandit-Taskar N, Hassoun H, Cohen A, Lesokhin A, Lendvai N, Drullinsky P, Schulman P, Jhanwar S, Hoover E, Bello C, Riedel E, Nimer SD, Comenzo RL. Landau H, et al. Leuk Lymphoma. 2012 Feb;53(2):275-81. doi: 10.3109/10428194.2011.606943. Epub 2011 Sep 23. Leuk Lymphoma. 2012. PMID: 21824051 Clinical Trial.
Lenalidomide after stem-cell transplantation for multiple myeloma.
McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Richardson PG, Giralt S, Stadtmauer EA, Weisdorf DJ, Vij R, Moreb JS, Callander NS, Van Besien K, Gentile T, Isola L, Maziarz RT, Gabriel DA, Bashey A, Landau H, Martin T, Qazilbash MH, Levitan D, McClune B, Schlossman R, Hars V, Postiglione J, Jiang C, Bennett E, Barry S, Bressler L, Kelly M, Seiler M, Rosenbaum C, Hari P, Pasquini MC, Horowitz MM, Shea TC, Devine SM, Anderson KC, Linker C. McCarthy PL, et al. N Engl J Med. 2012 May 10;366(19):1770-81. doi: 10.1056/NEJMoa1114083. N Engl J Med. 2012. PMID: 22571201 Free PMC article. Clinical Trial.
Factors impacting stem cell mobilization failure rate and efficiency in multiple myeloma in the era of novel therapies: experience at Memorial Sloan Kettering Cancer Center.
Pozotrigo M, Adel N, Landau H, Lesokhin A, Lendvai N, Chung DJ, Chimento D, Riedel E, Chen X, Reich L, Comenzo R, Giralt S, Hassoun H. Pozotrigo M, et al. Bone Marrow Transplant. 2013 Aug;48(8):1033-9. doi: 10.1038/bmt.2012.281. Epub 2013 Jan 21. Bone Marrow Transplant. 2013. PMID: 23334269
140 results